Cocrystal Pharma’s (COCP) Buy Rating Reaffirmed at HC Wainwright

Cocrystal Pharma (NASDAQ:COCP)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 239.81% from the company’s current price.

Cocrystal Pharma Stock Up 3.0 %

NASDAQ:COCP opened at $2.06 on Wednesday. The business’s 50-day moving average price is $2.16 and its 200 day moving average price is $1.99. The firm has a market cap of $20.95 million, a P/E ratio of -1.11 and a beta of 1.53. Cocrystal Pharma has a 52-week low of $1.33 and a 52-week high of $3.26.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.